Otonomy, Inc. (OTIC): Price and Financial Metrics


Otonomy, Inc. (OTIC): $2.26

0.01 (+0.44%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add OTIC to Watchlist
Sign Up

Industry: Biotech


Ranked

of 487

in industry

OTIC POWR Grades


  • Growth is the dimension where OTIC ranks best; there it ranks ahead of 72.12% of US stocks.
  • The strongest trend for OTIC is in Momentum, which has been heading down over the past 31 weeks.
  • OTIC's current lowest rank is in the Momentum metric (where it is better than 9.33% of US stocks).

OTIC Stock Summary

  • With a price/sales ratio of 627.54, Otonomy Inc has a higher such ratio than 98.57% of stocks in our set.
  • Revenue growth over the past 12 months for Otonomy Inc comes in at -64.26%, a number that bests merely 4.35% of the US stocks we're tracking.
  • Otonomy Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -50.76%, greater than the shareholder yield of only 4.76% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Otonomy Inc, a group of peers worth examining would be CAPR, CLSN, VBIV, BCDA, and SRRA.
  • Visit OTIC's SEC page to see the company's official filings. To visit the company's web site, go to www.otonomy.com.

OTIC Price Target

For more insight on analysts targets of OTIC, see our OTIC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $5.63 Average Broker Recommendation 1.4 (Strong Buy)

OTIC Stock Price Chart Interactive Chart >

Price chart for OTIC

OTIC Price/Volume Stats

Current price $2.26 52-week high $6.98
Prev. close $2.25 52-week low $2.01
Day low $2.20 Volume 110,244
Day high $2.30 Avg. volume 801,336
50-day MA $2.30 Dividend yield N/A
200-day MA $3.69 Market Cap 127.96M

Otonomy, Inc. (OTIC) Company Bio


Otonomy Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear. The company was founded in 2008 and is based in San Diego, California.


OTIC Latest News Stream


Event/Time News Detail
Loading, please wait...

OTIC Latest Social Stream


Loading social stream, please wait...

View Full OTIC Social Stream

Latest OTIC News From Around the Web

Below are the latest news stories about Otonomy Inc that investors may wish to consider to help them evaluate OTIC as an investment opportunity.

Looking Into Otonomy''s Return On Capital Employed

During Q1, Otonomy ''s (NASDAQ: OTIC ) reported sales totaled $90.00 thousand. Despite a 15.13% in earnings, the company posted a loss of $11.84 million. Otonomy collected $53.00 thousand in revenue during Q4, but reported earnings showed a $10.29 million loss. What Is ROCE? Changes in earnings and sales indicate shifts in Otonomy''s Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful Full story available on Benzinga.com

Benzinga | June 17, 2021

In the clinic for June 16, 2021

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Clearside, Fibrogen, Fusion, Ironwood, KBP, Lundbeck, Novadip, Oncotelic, Organicell, Otonomy, Paratek, Regeneron, Reviral, Salarius, Springworks, Trevena.

BioWorld | June 16, 2021

Otonomy announces phase I/II study expansion for OTO-413 in speech-in-noise hearing difficulty

No summary available.

BioWorld | June 16, 2021

Increases to CEO Compensation Might Be Put On Hold For Now at Otonomy, Inc. (NASDAQ:OTIC)

The underwhelming share price performance of Otonomy, Inc. ( NASDAQ:OTIC ) in the past three years would have...

Yahoo | June 16, 2021

Otonomy Initiates Expansion of Phase 1/2 Clinical Trial for OTO-413 in Hearing Loss

OTO-413 demonstrated a higher proportion of responders than placebo based on multiple speech-in-noise hearing tests in dose escalation efficacy cohortExpansion study will support endpoint selection and powering for Phase 2Top-line results expected in mid-2022 SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the initiation of an expansion study for the Pha

Yahoo | June 15, 2021

Read More 'OTIC' Stories Here

OTIC Price Returns

1-mo -1.74%
3-mo -14.72%
6-mo N/A
1-year -39.25%
3-year -43.50%
5-year -85.49%
YTD -65.07%
2020 68.93%
2019 107.03%
2018 -66.67%
2017 -65.09%
2016 -42.70%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7417 seconds.